propionic acidemia

propionic acidemia
Name	Propionic acidemia
Synonyms	Propionyl-CoA carboxylase deficiency
Field	Medical genetics, Metabolic disorder
Symptoms	Lethargy, Vomiting, Hypotonia, Seizure
Complications	Cardiomyopathy, Developmental delay, Metabolic acidosis
Onset	Neonatal period
Duration	Lifelong
Causes	Mutations in PCCA or PCCB
Risks	Autosomal recessive inheritance
Diagnosis	Newborn screening, GC-MS, Enzyme assay
Differential	Methylmalonic acidemia, Isovaleric acidemia
Prevention	Genetic counseling
Treatment	Dietary management, Carnitine, Antibiotic
Medication	L-Carnitine, Metronidazole
Prognosis	Variable; risk of neurological impairment
Frequency	~1 in 100,000 to 150,000

propionic acidemia. Propionic acidemia is an inherited autosomal recessive disorder of branched-chain amino acid metabolism caused by a deficiency of the enzyme propionyl-CoA carboxylase. This defect leads to the toxic accumulation of propionic acid and related compounds, resulting in severe, often life-threatening metabolic decompensation. It is one of the most common organic acidemias identified through expanded newborn screening programs worldwide. The condition was first described in detail by Y. E. Hsia and colleagues in the early 1970s.

Signs and symptoms

Clinical presentation is highly variable, ranging from a catastrophic neonatal onset form to a later-onset, more chronic course. The classic neonatal form manifests within the first days of life with profound lethargy, poor feeding, recurrent vomiting, and hypotonia, rapidly progressing to metabolic acidosis, hyperammonemia, and seizures. Chronic symptoms in survivors or later-presenting individuals can include failure to thrive, developmental delay, movement disorders such as dystonia, and pancreatitis. Long-term complications frequently involve the cardiovascular system, with cardiomyopathy being a major cause of morbidity, and the central nervous system, leading to intellectual disability and basal ganglia lesions visible on magnetic resonance imaging.

Genetics

Propionic acidemia is caused by mutations in either the PCCA gene located on chromosome 13 or the PCCB gene located on chromosome 3. These genes encode the alpha and beta subunits, respectively, of the mitochondrial enzyme propionyl-CoA carboxylase. Inheritance follows an autosomal recessive pattern, meaning an affected individual must inherit a defective copy of the gene from both carrier parents. Hundreds of pathogenic variants have been reported across diverse populations, with certain mutations showing higher frequency in specific groups, such as the c.1606A>G variant in the PCCA gene among the Old Order Amish of Lancaster County.

Pathophysiology

The primary defect is a deficiency in propionyl-CoA carboxylase, a biotin-dependent enzyme crucial for the catabolism of isoleucine, valine, threonine, methionine, and odd-chain fatty acids. This blocks the conversion of propionyl-CoA to methylmalonyl-CoA, a step in the citric acid cycle. Consequently, propionyl-CoA and its derivatives, including propionic acid, methylcitrate, and propionylglycine, accumulate intracellularly. This disrupts multiple mitochondrial pathways, causing secondary inhibition of the urea cycle leading to hyperammonemia, depletion of free carnitine, and inhibition of pyruvate dehydrogenase complex, which collectively result in energy crisis, ketoacidosis, and cellular toxicity, particularly in the brain and heart.

Diagnosis

Diagnosis is often first suggested by abnormal results on tandem mass spectrometry as part of newborn screening, showing elevated levels of propionylcarnitine. Confirmatory biochemical testing involves analyzing urine organic acids via gas chromatography-mass spectrometry, which reveals markedly elevated excretion of methylcitrate, 3-hydroxypropionate, and propionylglycine. Plasma acylcarnitine profile confirms elevated C3-carnitine. Definitive diagnosis is achieved by demonstrating deficient propionyl-CoA carboxylase activity in leukocytes or fibroblasts, or through molecular genetic testing to identify mutations in the PCCA gene or PCCB gene. Prenatal diagnosis is possible via amniocentesis or chorionic villus sampling.

Management

Acute management of metabolic crises requires aggressive intervention in a hospital setting to correct metabolic acidosis with sodium bicarbonate, reduce hyperammonemia possibly with hemodialysis, and provide high-energy intravenous dextrose to halt catabolism. Long-term management is centered on a strict, lifelong protein-restricted diet designed by a metabolic dietitian, utilizing special medical foods deficient in the precursor amino acids. Supplementation with L-carnitine is standard to correct deficiency and enhance excretion of toxic metabolites. Intermittent use of metronidazole or other antibiotics aims to reduce production of propionate by gut flora. Regular monitoring by a team including a metabolic geneticist is essential.

Prognosis

The prognosis remains guarded and is largely dependent on the severity and frequency of metabolic decompensations, particularly in the neonatal period. Despite advances in newborn screening and dietary management, many individuals experience significant neurodevelopmental impairment, including cognitive deficits and extrapyramidal symptoms. The risk of life-threatening complications, such as sudden cardiac death from cardiomyopathy or severe metabolic stroke during illness, persists throughout life. Outcomes are generally more favorable for those with the later-onset variant, but all patients require meticulous, lifelong medical supervision.

Category:Inborn errors of metabolism Category:Autosomal recessive disorders